928659-70-5 Usage
Description
Eliglustat tartrate, developed and marketed by Genzyme Corporation
(a subsidiary of Sanofi), was approved by the US FDA in
August 2014 for the treatment of nonneuropathic (type 1) Gaucher
disease (GD1) in both treatment-naive and treatment-experienced
adult patients. It is the first oral treatment to be approved for
first-line use in patients with Gaucher disease type 1, which is a
rare lysosomal storage disease characterized by accumulation of lipid glucosylceramide (GL-1) due to insufficient production of the
enzyme glucosylceramidase. Clinical complications include
hepatosplenomegaly, anemia, thrombocytopenia, and bone
involvement. Eliglustat is a specific inhibitor of glucosylceramide
synthase with an IC50 of 10 ng/mL and acts as substrate
reduction therapy for GD1; it has demonstrated non-inferiority
to enzyme replacement therapy, which is the current standard of
care, in Phase III trials.
Uses
Eliglustat Tartrate functions as an oral agent for treatment of Gaucher disease type 1, and lysosomal storage disorders in human. It also inhibits UDP-glucosylceramide synthase in mice thereby preventing Gaucher disease-associated with B-cell malignancy.
Definition
ChEBI: A tartrate that is the hemitartrate salt of eliglustat. A ceramide glucosyltransferase inhibitor used (as its tartrate salt) for treatment of Gaucher's disease.
Synthesis
Condensation of commercially available
S-(+)-2-phenyl glycinol (87) with phenyl bromoacetate (88)
in acetonitrile in the presence of N,N-diisopropylethylamine
(DIPEA) provided morpholin-2-one 89 upon treatment with HCl.
Neutralization with NaHCO3 followed by coupling with aldehyde
90 in refluxing EtOAc/toluene yielded oxazine adduct 91, which
was isolated as a precipitate from methyl-tert-butyl ether (MTBE).
The stereochemistry of the three new stereocenters in 91 can be
rationalized through the cycloaddition of an ylide intermediate in
the sterically-preferred S-configuration (generated by the reaction
of the morpholinone 89 with aldehyde 90) with a second equivalent
of the aldehyde. With the morpholinone in a chair conformation
in which the phenyl group is equatorial, endo axial approach
of the dipolarophile to the less-hindered face of the ylide and subsequent
ring flip of the morpholinone ring to a boat conformation
positions all exocyclic aryl substituents in a pseudoequatorial configuration.
Opening of oxazine 91 with pyrrolidine in refluxing
THF followed by addition of HCl in refluxing MeOH gave amide
92, which was reduced to amine 93 using LiAlH4 in refluxing
THF. Subsequent hydrogenation with Pd(OH)2 in EtOH cleaved
the phenylethanol group to give the free amine, which was converted
to dioxalate salt 94 by treatment with oxalic acid in methyl
isobutylketone (MIBK). Subjection of aminoethanol 94 to aqueous
sodium hydroxide followed by coupling with palmitic acid Nhydroxysuccinimide
(NHS)-ester (95) gave eliglustat as the corresponding
freebase (96) in 9.5% overall yield from 87. Salt formation
with L-tartaric acid (0.5 equiv) then provided eliglustat tartrate
(XII).
Check Digit Verification of cas no
The CAS Registry Mumber 928659-70-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,8,6,5 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 928659-70:
(8*9)+(7*2)+(6*8)+(5*6)+(4*5)+(3*9)+(2*7)+(1*0)=225
225 % 10 = 5
So 928659-70-5 is a valid CAS Registry Number.
